Today BMO Capital reiterates its “hold” rating on Abbott Labs (NYSE: ABT) and a target price of $ 53.0 – tech2.org

Today BMO Capital reiterates its “hold” rating on Abbott Labs (NYSE: ABT) and a target price of $ 53.0



[ad_1]

<! –

News Stock

->

December 2, 2017 – By Darrin Black

   Today BMO Capital reiterates

Investor confidence fell to 0.88 in the 2Q of 2017. Its decline was 0.75, from 1.63 in 2017Q1. It falls, as 69 investors sold shares of Abbott Laboratories while 545 shares declined. 102 funds opened positions, while 441 increased positions. 1.22 billion shares or 0.83% more than 1.21 billion shares in 2017Q1 were reported.

Security Comml Bank of Sioux City Iowa accumulated 0% or 70 shares. Blue Fin accumulated 17,954 shares or 0.56% of the shares. Bessemer Inc, based in New Jersey, has invested 0.01% in Abbott Laboratories (NYSE: ABT). In addition, Sterling Ltd Liability Com has 1.11% invested in Abbott Laboratories (NYSE: ABT) for 2.37 million shares. Verity Verity owns 142,097 shares. Congress Asset Com Ma accumulated 9,234 shares or 0.01% of the shares. Beacon Fin Grp reported 23,136 participation shares. Toth Finance Advisory Corporation owns 144,021 shares or 1.83% of its portfolio in the United States. Gamco Et Al owns 0.02% invested in Abbott Laboratories (NYSE: ABT) for 67,633 shares. Cornerstone Advsr Incorporated accumulated 0.52% or 58,000 shares. Janney Montgomery Scott Limited Liability Co owns 372,055 shares or 0.23% of its portfolio. Green Valley Ltd Liability Corporation stated that it has 2.17 million shares or 5.15% of all its holdings. Texan Cap Management has invested 0.19% of its portfolio in Abbott Laboratories (NYSE: ABT). Parsons Cap Inc Ri has invested 0.7% in Abbott Laboratories (NYSE: ABT). In addition, Estabrook has 0% invested in Abbott Laboratories (NYSE: ABT).

As of June 15, 2017, it had 0 purchases and 1 sale for $ 26,482 of activity.

The rating of Abbott Labs (NYSE: ABT)

was reaffirmed BMO Capital now has a price target of $ 53.0 for the shares of Abbott Labs (NYSE: ABT) . The target price suggests a possible disadvantage of -5.32% since the last closing of stocks of Abbott Labs (NYSE: ABT) . This qualification was revealed in a research report on October 2.

Investor confidence decreased to 0.88 in the second quarter of 2017. Its decline was 0.75, from 1.63 in 2017Q1. It falls, as 69 investors sold shares of Abbott Laboratories while 545 shares declined. 102 funds opened positions, while 441 increased positions. 1.22 billion shares or 0.83% more than 1.220 million shares were reported in 2017Q1.

Security Comml Bank of Sioux City Iowa Ia accumulated 0% or 70 shares. Blue Fin accumulated 17,954 shares or 0.56% of the shares. Bessemer Inc, based in New Jersey, has invested 0.01% in Abbott Laboratories (NYSE: ABT). In addition, Sterling Ltd Liability Com has 1.11% invested in Abbott Laboratories (NYSE: ABT) for 2.37 million shares. Verity Verity owns 142,097 shares. Congress Asset Com Ma accumulated 9,234 shares or 0.01% of the shares. Beacon Fin Grp reported 23,136 participation shares. Toth Finance Advisory Corporation owns 144,021 shares or 1.83% of its portfolio in the United States. Gamco Et Al owns 0.02% invested in Abbott Laboratories (NYSE: ABT) for 67,633 shares. Cornerstone Advsr Incorporated accumulated 0.52% or 58,000 shares. Janney Montgomery Scott Limited Liability Co owns 372,055 shares or 0.23% of its portfolio. Green Valley Ltd Liability Corporation stated that it has 2.17 million shares or 5.15% of all its holdings. Texan Cap Management has invested 0.19% of its portfolio in Abbott Laboratories (NYSE: ABT). Parsons Cap Inc Ri has invested 0.7% in Abbott Laboratories (NYSE: ABT). In addition, Estabrook has 0% invested in Abbott Laboratories (NYSE: ABT).

As of June 15, 2017, it had 0 purchases and 1 sale for $ 26,482 of activity.

Abbott Laboratories (NYSE: ABT)

Ratings Coverage Among the 24 badysts covering Abbott Laboratories (NYSE: ABT), 14 are Buy, 0 Sell and 10 Hold. Therefore, 58% are positive. Abbott Laboratories has a higher goal of $ 90 and a minimum of $ 4. The average goal of $ 50.80 is -9.25% below current $ 55.98 share price. Abbott Laboratories had 87 badyst reports from July 24, 2015 according to SRatingsIntel. The shares of Abbott Laboratories (NYSE: ABT) were rated "Market Perform" by William Blair on Friday, January 29. The firm has an "Overweight" rating awarded on Thursday, October 19 by Barclays Capital. As on Tuesday, March 15, Jefferies maintained the company's rating. The action is rated "Buy" by BTIG Research on Saturday, August 29. The qualification was maintained by Morgan Stanley on Tuesday, July 11 with "Equal-Weight". Jefferies kept it with a "Buy" rating and a goal of $ 58.0 in the report on Tuesday, September 5. Wells Fargo held the ABT shares in the report on Thursday, August 27 with the "Buy" rating. The firm obtained an "Overweight" rating on Thursday, April 20 from Barclays Capital. The action is rated "Maintain" by Northland Capital on Thursday, September 28. BMO Capital Markets maintained the "Keep" rating action in the report on Thursday, August 31.

The share declined 0.69% or $ 0.39 during the last trading session. reaching $ 55.98. Approximately 5.32 million shares traded. Abbott Laboratories (NYSE: ABT) has risen 15.90% since December 2, 2016 and is trending upward. The S & P500 has underperformed 0.80%.

Analysts expect Abbott Laboratories (NYSE: ABT) to report earnings on January 24. They expect earnings of $ 0.73 per share, 12.31% or $ 0.08 last year $ 0.65 per share. The earnings of ABT will be $ 1.27 billion for 19.17 P / E if the EPS of $ 0.73 becomes a reality. After real earnings per share of $ 0.66 reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts an EPS growth of 10.61%.

Abbott Laboratories manufactures and sells health care products around the world. The company has a market capitalization of $ 97.44 billion. The company's established pharmaceuticals segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; Irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; Hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever and inflammation; migraines; anti-infectious clarithromycin; cardiovascular and metabolic products; and vaccines against influenza, as well as to regulate the physiological rhythm of the colon. It has a P / E ratio of 78.4. The company's diagnostic products segment provides immunobadays and clinical chemistry systems; tests used to detect and / or diagnose cancer, heart problems, drugs of abuse, fertility, infectious diseases and therapeutic drug control; hematology and reagent systems; diagnostic systems and cartridges; instruments to automate the extraction, purification and preparation of DNA and RNA from patient samples, and to detect and measure infectious agents; genomic tests; computer and automation solutions; and a set of computer tools and professional services.

The latest highlights from Abbott Laboratories (NYSE: ABT) were published by: Investorplace.com, which launched: "Earnings Momentum converts Abbott Laboratories (ABT) into a purchase" on November 21. 2017, also Businesswire.com with its article: "Global Blood Testing Market 2017-2021 with Abbott Laboratories, Bio-Rad …" published on November 28, 2017, Investorplace.com published: "Abbott Laboratories & # 39; ABT) High-level sales Make it to Buy "on November 7, 2017. More interesting news about Abbott Laboratories (NYSE: ABT) was published by: Investorplace.com and its article:" Trade of the Day: Abbott Laboratories ( ABT) "published on November 20. , 2017, as well as the Investorplace.com news article titled: "Abbott Laboratories (ABT) a purchase in Strong Quant Score" with publication date: November 28, 2017.

Receive news and ratings by email – Enter your email address below to receive a concise summary of the latest news and badyst ratings with our FREE daily newsletter via email.


[ad_2]
Source link

Leave a Reply

Your email address will not be published.